HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA Cosmetics Twitter; Eyebrow Makeup Sales; Olay ProX Study

This article was originally published in The Rose Sheet

Executive Summary

FDA’s Office of Cosmetics and Colors starts tweeting, NPD says prestige eyebrow makeup sales are an opportunity for growth. More news in brief.

You may also be interested in...



FDA Advances Work On Chemical-Hazard Early-Detection Program

In a recent contract solicitation announcement, FDA’s Center for Food Safety and Applied Nutrition offers insight into its developing “early warning” system for potential chemical hazards in cosmetics, dietary supplements and foods. The agency seeks a contractor with expertise to mine data and identify potential risks based on hazard “signals” across a spectrum of information sources.

China Probe Finds Issues With Nu Skin Compliance, Not Business Model

Nu Skin’s direct-selling model in China, the legality of which some investors have questioned, was not cited in fines levied on the company totaling $540,000. Firm says it “is not aware of any other material enforcement investigations currently pending” in the country, which accounted for nearly half of Nu Skin’s fiscal 2013 fourth-quarter sales.

Olay Professional Pro-X Performs On Par With Top Rx Brand, At Half The Price?

Procter & Gamble is going after consumers who demand a bang for their buck with its wrinkle-targeting Olay Professional Pro-X line, which it claims offers Rx results at a much-reduced price

Related Companies

UsernamePublicRestriction

Register

RS019111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel